The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
Gene therapy has been in the news a lot of late as a potential cure for a variety of genetic diseases.
The biggest breakthrough involved a unanimous backing from U.S. Food and Drug Administration's advisory panel for a new gene therapy from Spark Therapeutics, intended to treat rare eye diseases. But what exactly is gene therapy, and does it deserve all that hype?
CNBC sat down with Canaan Venture Partners' biotech investor Nina Kjellson for a simple explanation of how it all works, and why she's excited about it. As Kjellson explains, in the most simple terms, gene therapy is a technique that uses genes to treat disease.
The first patients were tested about twenty-five years ago, but early trials were not uniformly successful. In one notable case, it led to the death of 18-year-old Jesse Gelsinger, who got an infusion of trillions of genetically engineered viruses into his liver.
Spark has seen some better results for its therapy, which treats a rare condition that causes a form of blindness that often starts in childhood.
Its treatment involves using a modified version of a virus to carry a healthy version of the gene into the retina. Think of it as a good copy of the gene.
The crazy part? Doctors will inject billions of these viruses — or "vectors" — into both of the patient's eyes to reach the cells where it's needed.
The FDA hasn't approved Spark's therapy just yet, but it usually follows the advice of the advisory committee.
A big obstacle remains — and that's price. The cost for each patient could be as high as $1 million, which insurance companies might decline to cover.
For Kjellson, these experimental therapies have a lot of promise as they could treat a wide variety of medical conditions, starting with genetic disorders caused by mutations in single genes.
It's still early days, but the hope is that gene therapy might someday replace drugs or surgery by fixing the problem at its root.